EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP

Kata Kelen, Orsolya Horváth iD, Éva Kis, Bálint Mikes, Péter Sallay, Zoltán Prohászka, Attila József Szabó, György S Reusz

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241814389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Kata Kelen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bókay Street Unit, Department of Pediatrics, Semmelweis University, 1083 Budapest, Hungary. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Atypical Hemolytic Uremic Syndrome, Immunosuppressive Agents, Immunosuppression Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Office (NKFIH) Hungary, National Research, Development and Innovation Office (NKFIH), Semmelweis University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent classification of pediatric thrombotic microangiopathies (TMA) takes into consideration mechanisms of disease for guidance to targeted therapies. We present our experience with seven patients with antibody mediated atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP). Five children had aHUS with antibodies against complement factor H (CFH-ab) and two with TTP with antibodies against metalloproteinase ADAMTS13. In the aHUS cases diagnosed and treated before the eculizumab era, CFH-ab was detected using the ELISA assay. Mutational analysis of selected complement genes was performed. TTP was diagnosed if, in addition to microangiopathic hemolytic anemia and thrombocytopenia, ischemic organ involvement and severe deficiency in ADAMTS13 activity were present. Treatment protocol consisted of plasma exchanges (PE) and steroid pulses, followed by the combination of cyclophosphamide and rituximab to achieve long-term immunosuppression. Four patients with CFH-ab and the TTP patients with ADAMTS13 antibodies came into sustained remission. After a median follow-up of 11.7 (range 7.7–12.9) years without maintenance therapy, no disease recurrence was observed; nevertheless, six patients, two had hypertension and two had proteinuria as a late consequence. One patient, with late diagnosis of CFH-ab and additional genetic risk factors who was treated only with PE and plasma substitution, reached end-stage renal disease and was later successfully transplanted using eculizumab prophylaxis. In the cases of antibody-mediated TMAs, PE and early immunosuppressive treatment may result in sustained remission with preserved kidney function. Further data are needed to establish optimal treatment of anti-FH antibody-associated HUS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicAtypical Hemolytic Uremic SyndromeImmunosuppressive AgentsImmunosuppression TherapyHumansFemaleMaleChildComplement Factor HADAMTS13 ProteinAdolescentChild, PreschoolPlasma ExchangeAutoantibodiesRituximabInfant

Stichwörter der Autor:innen

TTPaHUSeculizumabimmunosuppressionthrombotic microangiopathy

Substanzen

Complement Factor HADAMTS13 ProteinImmunosuppressive AgentsADAMTS13 protein, humanAutoantibodiesRituximab

Autor:innen und Institutionen

  • Bókay Street Unit, Department of Pediatrics, Semmelweis University, 1083 Budapest, Hungary.
  • Department of Pediatric Cardiology, Gottsegen György Hungarian Institute of Cardiology, 1096 Budapest, Hungary.
  • Research Laboratory, Department of Medicine and Hematology, Semmelweis University, 1083 Budapest, Hungary.
  • Pediatric Center, MTA Center of Excellence, Semmelweis University, 1083 Budapest, Hungary.
  • ELKH-SE Pediatrics and Nephrology Research Group, 1052 Budapest, Hungary.

ORCID-Profile: Orsolya Horváth

Förderung

  • National Research, Development and Innovation Office (NKFIH) Hungary
  • National Research, Development and Innovation Office (NKFIH)
  • Semmelweis University

Zitieren

APA

Kelen, K., Horváth, O., Kis, É., Mikes, B., Sallay, P., Prohászka, Z., Szabó, A. J., & Reusz, G. S. (2023). Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241814389

Vancouver

Kelen K, Horváth O, Kis É, Mikes B, Sallay P, Prohászka Z, et al. Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241814389

BibTeX
@article{Kelen2023,
  author = {Kelen, Kata and Horváth, Orsolya and Kis, Éva and Mikes, Bálint and Sallay, Péter and Prohászka, Zoltán and Szabó, Attila József and Reusz, György S},
  title = {Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241814389}
}
Kostenlos starten →